Indeed, until PD-L1 testing is standardized and can consistently predict treatment outcome, the currently available PD-L1 assays are not clinically useful in urothelial and renal cell carcinoma. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.